postencephalitic Parkinson disease
diseaseOn this page
Also known as postencephalitic Parkinsonism
Summary
postencephalitic Parkinson disease (MONDO:0001945) is a disease. A subtype of secondary Parkinson disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Phenotypes (HPO): 41
Clinical features
Signs & symptoms
Clinical features (HPO)
41 HPO clinical features (Orphanet curated; top 41 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0002322 | Resting tremor | Very frequent (80-99%) |
| HP:0001945 | Fever | Frequent (30-79%) |
| HP:0002067 | Bradykinesia | Frequent (30-79%) |
| HP:0002329 | Drowsiness | Frequent (30-79%) |
| HP:0002396 | Cogwheel rigidity | Frequent (30-79%) |
| HP:0002465 | Poor speech | Frequent (30-79%) |
| HP:0003324 | Generalized muscle weakness | Frequent (30-79%) |
| HP:0003487 | Babinski sign | Frequent (30-79%) |
| HP:0004305 | Involuntary movements | Frequent (30-79%) |
| HP:0007256 | Abnormal pyramidal sign | Frequent (30-79%) |
| HP:0010553 | Oculogyric crisis | Frequent (30-79%) |
| HP:0000718 | Aggressive behavior | Occasional (5-29%) |
| HP:0000194 | Open mouth | Occasional (5-29%) |
| HP:0000496 | Abnormality of eye movement | Occasional (5-29%) |
| HP:0000514 | Slow saccadic eye movements | Occasional (5-29%) |
| HP:0000716 | Depression | Occasional (5-29%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0001260 | Dysarthria | Occasional (5-29%) |
| HP:0001488 | Bilateral ptosis | Occasional (5-29%) |
| HP:0002013 | Vomiting | Occasional (5-29%) |
| HP:0002015 | Dysphagia | Occasional (5-29%) |
| HP:0002063 | Rigidity | Occasional (5-29%) |
| HP:0002304 | Akinesia | Occasional (5-29%) |
| HP:0002315 | Headache | Occasional (5-29%) |
| HP:0002374 | Diminished movement | Occasional (5-29%) |
| HP:0002381 | Aphasia | Occasional (5-29%) |
| HP:0002795 | Abnormal respiratory system physiology | Occasional (5-29%) |
| HP:0002808 | Kyphosis | Occasional (5-29%) |
| HP:0003401 | Paresthesia | Occasional (5-29%) |
| HP:0005329 | Fixed facial expression | Occasional (5-29%) |
| HP:0006801 | Hyperactive deep tendon reflexes | Occasional (5-29%) |
| HP:0008765 | Auditory hallucinations | Occasional (5-29%) |
| HP:0011446 | Abnormality of higher mental function | Occasional (5-29%) |
| HP:0012735 | Cough | Occasional (5-29%) |
| HP:0025331 | Upgaze palsy | Occasional (5-29%) |
| HP:0025456 | Abnormal CSF protein level | Occasional (5-29%) |
| HP:0030188 | Tremor by anatomical site | Occasional (5-29%) |
| HP:0040082 | Happy demeanor | Occasional (5-29%) |
| HP:0045007 | Abnormality of the substantia nigra | Occasional (5-29%) |
| HP:0100595 | Camptocormia | Occasional (5-29%) |
| HP:0200149 | CSF lymphocytic pleiocytosis | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | postencephalitic Parkinson disease |
| Mondo ID | MONDO:0001945 |
| EFO | EFO:1001402 |
| MeSH | D010301 |
| Orphanet | 97349 |
| DOID | DOID:14332 |
| ICD-10-CM | G21.3 |
| NCIT | C34898 |
| SNOMED CT | 19972008 |
| UMLS | C0030568 |
| MedGen | 10591 |
| GARD | 0019370 |
| Is cancer (heuristic) | no |
Also known as: postencephalitic Parkinsonism · postencephalitic parkinsonism
Disease family
This is a subtype of secondary Parkinson disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › neurodegenerative disease › secondary Parkinson disease › postencephalitic Parkinson disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.